A Phase I/II Study of NPC-22 in Patients with Amyotrophic Lateral Sclerosis - NPC-22-4

Katsunori Miyoshi0 个研究点目标入组 15 人开始时间: 2022年2月17日最近更新: 2023年10月17日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 15

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 <= 80age old（—）
性别: All

入选标准

•The Japanese ALS patients who meet all inclusion criteria
•(1) Patients who have provided their own written informed consent, who have complied with the requirements for participation in the study, who have undergone the medical examinations and tests specified in the study protocol, and who are able to report their symptoms, etc.
•(2) Patients aged =>20 and =<80 years at the time of imformed consent, regardless of gender
•(3) Patients who meet either definite or probable of the revised Airlie House diagnostic criteria for El Escorial
•(4) Patients with drooling (salivary secretion below 3 on ALSFRS-R for more than 28 days) whose volume can be measured

排除标准

•(1) Patients with malignant tumors undergoing treatment
•(2) Patients who are suffering or have a history of any skin disease or skin abnormality at the site of study drug administration (postauricular area) that may prevent evaluation or are receiving treatment at the site of study drug administration that may prevent evaluation (e.g., topical corticosteroids)
•(3) Patients who have previously received treatment that affects the salivary glands (botulinum toxin injection, surgery, or radiation therapy)
•(4) Patients who have received medication to treat drooling within 14 days (Day-14) prior to the start of study drug administration
•(5) Patients with significant dental or oral lesions.
•(6) Patients who are hypersensitive to scopolamine or atropine (belladonna alkaloid) or have a complication or a history of drug allergy
•(7) Patients with any concurrent illnesses such as angle closure glaucoma, open angle glaucoma, benign prostatic hyperplasia, urinary retention, severe heart disease, congestive heart failure, arrhythmia, paralytic ileus, pyloric stenosis, ileus, ulcerative colitis, asthma, hyperthyroidism, epilepsy, hepatitis who are judged by the investigator or sub-investigator to be ineligible for participation in the study
•(8) Patients with infectious diseases requiring treatment who are judged by the investigator or sub-investigator to be ineligible for participation in the study.
•(9) Patients who are unable to cooperate with contraception from the time of obtaining consent until the end of observation
•(10) Patients who are premenopausal (Menopause is defined here as the absence of menstruation for more than 12 months without any other medical reason)
•(11) Patients who received another study drug within 12 weeks prior to the start of study drug administration
•(12) Patients who are unsuitable as a subject in this study in the judgement of the principal investigator or a sub-investigator due to other reasons

研究者

发起方

Katsunori Miyoshi

相似试验

已完成

1 期

Repeated dose study of NPC-22Sialorrhea

JPRN-jRCT2031210169Miyoshi Katsunori16

进行中（未招募）

1 期

Brighton: PNT2258 for Treatment of Patients with Richter's TransformatioDiffuse large B-cell non-Hodgkin's lymphoma with Richter's Transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)MedDRA version: 18.1Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2015-001814-85-GBProNAi Therapeutics, Inc.5

进行中（未招募）

1 期

EUCTR2015-001814-85-HUProNAi Therapeutics, Inc.49

进行中（未招募）

1 期

Brighton: PNT2258 for Treatment of Patients with Richter's Transformatio

EUCTR2015-001814-85-BEProNAi Therapeutics, Inc.49

未知

1 期

Phase 1/2 study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophyDuchenne muscular dystrophy

JPRN-jRCT2080223236IPPON SHINYAKU CO., LTD.16